The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.00
Bid: 102.00
Ask: 106.00
Change: -1.50 (-1.42%)
Spread: 4.00 (3.922%)
Open: 105.50
High: 105.50
Low: 104.00
Prev. Close: 105.50
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

28 Dec 2016 07:00

RNS Number : 8003S
Intercede Group PLC
28 December 2016
 

 

 

 

28 December 2016

 

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

 

Interim Results for the Six Months Ended 30 September 2016

 

 

Intercede, the software and service company specialising in identity, credential management and secure mobility, today announces its interim results for the six months ended 30 September 2016.

 

Highlights

· Revenues of £2.8m (2015: £5.5m), a decrease of 49%.

 

· Operating expenses increased to £6.4m (2015: £5.7m), as a result of continuing investment in infrastructure, technology development and sales capacity.

 

· Headcount increased to 127 at 30 September 2016 (30 September 2015: 125).

 

· Operating loss of £3.7m (2015: £0.4m).

 

· Loss for the period of £2.8m (2015: profit of £0.5m).

 

· Basic loss per share 5.7p (2015: basic earnings per share 1.0p).

 

· Cash balances of £1.4m at 30 September 2016 (30 September 2015: £5.8m). Subsequently increased to £2.6m at 30 November 2016.

 

· Approximately £5.0m to be raised via a Convertible Loan Note instrument and Subscription Shares (announced separately today).

 

· New contracts, which will all contribute to revenues during the current financial year and beyond, include:

 

Initial proof of concept order from a major German car manufacturer, targeting the provision of secure digital trust to more than 500,000 employees and devices.

New license sale to a subsidiary of a major aerospace and defence company.

Initial tranche of licenses sold to a global biopharmaceutical company serving patients in 50 countries.

Further £0.7m of orders secured from a major US aerospace company for a MyID upgrade and support contract renewal.

 

Richard Parris, Chairman & Chief Executive of Intercede, said:

 

"The reduction in revenues in the first half of the financial year should not mask the scale of the market opportunity which we are positioned to exploit. We are very pleased at the support we have received from both new and existing investors who also understand this opportunity and are endorsing our strategy by subscribing for convertible loan notes and equity. We remain confident that the deferred orders which have affected the first half of the year will soon come to fruition and the outlook for the full year is in line with expectations. In the more medium term, we are equally confident that the technology we have developed to build a secure bond of trust between connected people and their devices will assume more and more importance in the markets for cloud-based applications, secure mobility and the Internet of Things."

 

ENQUIRIES

 

Intercede Group plc Tel. +44 (0)1455 558 111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

 

finnCap Tel. +44 (0)20 7220 0500

Stuart Andrews, Corporate Finance

Simon Hicks, Corporate Finance

 

Bell Pottinger Tel. +44 (0)7802 442486

Archie Berens

 

 

About Intercede

 

Intercede is a software and service company specializing in identity, credential management and secure mobility. Its solutions create a foundation of trust between connected people, devices and apps and combine expertise with innovation to provide world-class cybersecurity. Intercede has been delivering solutions to high profile customers, from the US and UK governments to some of the world's largest corporations, telecommunications providers and information technology firms, for over 20 years. Intercede's product portfolio includes MyID, an identity and credential management system that assigns trusted digital identities to employees citizens and machines. In 2015, Intercede launched MyTAM, enabling trusted applications to be loaded into a mobile device's Trusted Execution Environment (TEE), providing hardware-level security for Android apps. In 2016, Intercede launched RapID, a secure, easy to implement authentication service for mobile apps and cloud services to completely eliminate the need for passwords.

 

For more information visit: www.intercede.com

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.INTERCEDE GROUP plc

 

('Intercede', 'the Company' or 'the Group')

 

Interim Results for the Six Months Ended 30 September 2016

 

Chairman's Statement

 

Introduction

 

Intercede has benefited from six months of important strategic progress measured in terms of new partnerships, positive market developments and the initiation of critical proof of concept deployments for secure mobility and the Internet of Things. Unfortunately, during the same period we were affected by the deferment of a small number of particularly large orders. While none of these external delays are a comment on the fundamental strength of the business, the short term impact of more than £2m of sales being deferred is significant in terms of our ability to continue the scale of our investment in business expansion.

 

The Company has therefore implemented a plan to raise additional funding to ensure we are adequately resourced to exploit the opportunities we have created around future looking mobile and IOT digital trust solutions. I am pleased to say this fund raising has been successful and the Company has conditionally secured approximately £5.0m of additional cash via a conditional convertible loan note instrument and equity. This new funding will be principally deployed to ramp sales over the next two years in newly emerging regulatory markets in UK, Europe, Korea and the US. The funding has come from new institutions and seasoned technology entrepreneurs as well as some of our major existing investors. This demonstrates the confidence of our long term backers as well as illustrating that our strategic story resonates strongly with a new generation of technology and security savvy investors.

 

Additionally, we have removed more than £0.6m of annualized costs from the business compared to the start of the financial year without impacting our core delivery capabilities.

 

Financial Results

 

Revenues in the period totaled £2,828,000, a 49% reduction compared to the corresponding period last year. For the MyID platform, a large proportion of revenue is generated from US Government agencies, which have stalled investment decisions while bigger political events play out. We believe the conclusion of the US presidential race will result in a pick-up in the revenue run rate as business returns to normal and significant deferred orders - which, as noted above, amount to more than £2m - are realised.

 

For the Company's newer products, RapID and MyTAM, the work put into business development has resulted in the identification of target markets and talks with reference customers in each of those markets. A RapID solution with a wealth management company is expected to go live later in the year, along with a pilot for a large group of Italian banks. Intercede also continues to build on relationships with all of the major silicon designers and believes that the combined offering of RapID and MyTAM to the Internet of Things future is unmatched on the global stage. Both products are expected to generate significant revenues in future periods.

 

Planned investment in marketing and PR and business development of new markets, as outlined above, has resulted in a 14% increase in operating expenses from £5,670,000 to £6,448,000. The combined effect of planned investment and revenue deferment has resulted in an increase in operating losses from £447,000 to £3,678,000.

 

Staff costs continue to represent the main area of expense, representing 77% of total operating costs (2015: 78%). Intercede had 127 employees and contractors as at 30 September 2016 (30 September 2015: 125). The average number of employees and contractors during the period has risen to 128 (2015: 121).

 

An £898,000 taxation credit for the period (2015: £912,000 taxation credit) primarily reflects the 2016 Research & Development ("R&D") claim as a result of the investment activities outlined above. Whilst the 2015 R&D claim was received during September 2015, the 2016 claim was received during October 2016. The Group is a beneficiary of the UK Government's efforts to encourage innovation by allowing 130% (2015: 125%) of qualifying R&D expenditure to be offset against taxable profits and allowing 14.5% of the lower of R&D losses or taxable losses to be paid as tax credits.

 

A loss for the period of £2,773,000 (2015: profit of £480,000) resulted in a basic and a fully diluted loss per share of 5.7p (2015: basic earnings per share of 1.0p and a fully diluted earnings per share of 0.9p).

 

Cash balances as at 30 September 2016 totaled £1,377,000 compared to £5,289,000 as at 31 March 2016 and £5,767,000 as at 30 September 2015. As at 30 November 2016, cash balances had recovered to £2,567,000 due to the receipt of the 2016 R&D claim post period end and receipts from customers. Growth will continue to be funded through a combination of existing cash balances and the additional funding that has been announced separately to the Stock Exchange today.

 

Operational Highlights

 

There have been key wins in respect of product development and customer engagement, all of which will contribute to revenues in the current financial year and beyond:

 

· The successful completion of a proof of concept of a MyID virtual smartcard solution for a major German car manufacturer.

 

· Development of a RapID solution into an e-wallet application that is currently in trial and will be used by a large group of Italian banks.

 

· RapID has been implemented into an app for a London-based wealth management company that is expected to go live before the end of the year. This will enable their customers to perform transactions easily and securely, rather than calling to transact through a broker.

 

· Initial tranche of licenses sold to a global biopharmaceutical company serving patients in 50 countries.

 

· Signed memorandum of understandings with a number of silicon and IoT IP companies to develop collaborative digital trust solutions for connected devices.

 

· Taken leadership roles in a number of industry initiatives relating to digital trust and cyber security.

 

Strategy and Outlook

 

Intercede's strategy remains unchanged, despite the short term challenges: to grow its digital trust service and software business from a core of existing high value reference customers to a much broader range of industry sectors and customer size.

 

Intercede plans to achieve this by continuing to generate revenues in its historically strong markets and to reinvest in the significantly higher growth opportunity that is anticipated in the Cloud-enabled, application service centric, mobile and Internet of Things markets. Intercede has already developed much of the required core technology, such as its MyID and MyTAM platforms. The strategic focus is now moving to packaging Intercede's portfolio of IP assets into new combinations to provide innovative solutions to some of the most intractable challenges of the digital economy.

 

In the medium term, RapID will contribute more to revenue than MyTAM. Target markets for RapID include those that are impacted by new regulations in the financial services and consumer sectors such as Payment Services Directive 2 (PSD2) and the General Data Protection Regulations (GDPR). MyTAM will be essential for solutions to the Internet of Things market and we believe the upside of success in this market is huge. For example, trusted applications on mobile devices will increase convenience, privacy and security for everyday consumer and business applications and, by 2020, the Internet of Things market is estimated to be in excess of 50 billion devices with each 'thing' needing to validate the trustworthiness of its peers across a network. Each point of trust is an opportunity for Intercede to provide an enabling service.

 

Our expectations are for accelerating year on year growth and turning the tens of millions of MyID identities into hundreds of millions of RapID/MyTAM app users. Our confidence is growing commensurately that, in the longer term, Intercede is exceptionally well placed to capitalise on the market for digital trust services.

 

 

Richard Parris

Chairman & Chief Executive

28 December 2016

Consolidated Statement of Comprehensive Income

For the period ended 30 September 2016

6 months ended

30 September 2016

6 months ended

30 September 2015

Year ended 31 March

2016

£'000

£'000

£'000

Continuing operations

Revenue

2,828

5,547

11,004

Cost of sales

(58)

(324)

(410)

__________

__________

__________

Gross profit

2,770

5,223

10,594

Operating expenses

(6,448)

(5,670)

(12,511)

__________

__________

__________

Operating loss

(3,678)

(447)

(1,917)

Finance income

7

15

32

__________

__________

__________

Loss before tax

(3,671)

(432)

(1,885)

Taxation

898

912

892

__________

__________

__________

(Loss)/profit for the period

(2,773)

480

(993)

__________

__________

__________

Total comprehensive (expense)/income attributable to owners of the parent company

(2,773)

480

(993)

__________

__________

__________

(Loss)/earnings per share (pence)

- basic

(5.7)p

1.0p

(2.1)p

- diluted

(5.7)p

0.9p

(2.1)p

__________

__________

__________

Consolidated Balance Sheet

As at 30 September 2016

As at

 30 September 2016

As at

30 September 2015

As at

31 March

2016

£'000

£'000

£'000

Non-current assets

Property, plant and equipment

822

835

864

__________

__________

__________

Current assets

Trade and other receivables

2,718

1,812

1,146

Cash and cash equivalents

1,377

5,767

5,289

__________

__________

__________

4,095

7,579

6,435

__________

__________

__________

Total assets

4,917

8,414

7,299

__________

__________

__________

Equity

Share capital

491

487

487

Share premium account

232

232

232

Other reserves

1,508

1,508

1,508

Retained earnings

(1,441)

2,453

1,131

__________

__________

__________

Total equity attributable to owners of the parent company

790

4,680

3,358

__________

__________

__________

Non-current liabilities

Deferred revenue

77

210

122

__________

__________

__________

Current liabilities

Trade and other payables

1,745

1,109

1,795

Deferred revenue

2,305

2,415

2,024

__________

__________

__________

4,050

3,524

3,819

__________

__________

__________

Total liabilities

4,127

3,734

3,941

__________

__________

__________

Total equity and liabilities

4,917

8,414

7,299

__________

__________

__________

 

Consolidated Statement of Changes in Equity

For the period ended 30 September 2016

Share capital

Share premium

Other reserves

Retained earnings

Total

£'000

£'000

£'000

£'000

£'000

At 1 April 2016

487

232

1,508

1,131

3,358

Issue of ordinary shares

4

-

-

-

4

Purchase of own shares

-

-

-

(68)

(68)

Employee share option plan charge

-

-

-

47

47

Employee share incentive plan charge

-

-

-

222

222

Loss for the period and total comprehensive income

-

-

-

(2,773)

(2,773)

________

________

________

________

_______

At 30 September 2016

491

232

1,508

(1,441)

790

__--______

________

________

___________

_______

At 1 April 2015

487

232

1,508

2,257

4,484

Purchase of own shares

-

-

-

(488)

(488)

Employee share option plan charge

-

-

-

57

57

Employee share incentive plan charge

-

-

-

147

147

Profit for the period and total comprehensive expense

-

-

-

480

480

________

________

________

________

_______

At 30 September 2015

487

232

1,508

2,453

4,680

__--______

________

________

___________

_______

At 1 April 2015

487

232

1,508

2,257

4,484

Purchase of own shares

-

-

-

(610)

(610)

Employee share option plan charge

-

-

-

115

115

Employee share incentive plan charge

-

-

-

334

334

Employee treasury share transfer

-

-

-

28

28

Loss for the year and total comprehensive expense

-

-

-

(993)

(993)

________

________

________

________

_______

At 31 March 2016

487

232

1,508

1,131

3,358

__--______

________

________

___________

_______

 

Consolidated Cash Flow Statement

For the period ended 30 September 2016

6 months ended 30 September 2016

6 months ended 30 September 2015

Year ended

31 March 2016

£'000

£'000

£'000

Cash flows from operating activities

Operating loss

(3,678)

(447)

(1,917)

Depreciation

103

89

186

Employee share option plan charge

47

57

115

Employee share incentive plan charge

222

147

334

Employee unit incentive plan (credit)/charge

(4)

15

58

Employee treasury share transfer

-

-

28

(Increase) in trade and other receivables

(821)

(737)

(100)

(Decrease)/increase in trade and other payables

(46)

(32)

611

Increase/(decrease) in deferred revenue

236

413

(66)

Interest received

9

19

36

__________

__________

__________

Cash used in operations

(3,932)

(476)

(715)

Taxation (paid)/received

(24)

912

892

__________

__________

__________

Net cash (used in)/generated from operating activities

(3,956)

436

177

__________

__________

__________

Investing activities

Purchases of property, plant and equipment

(61)

(71)

(197)

__________

__________

__________

Cash used in investing activities

(61)

(71)

(197)

__________

__________

__________

Financing activities

Purchase of own shares

(64)

(488)

(610)

__________

__________

__________

Cash used in financing activities

(64)

(488)

(610)

__________

__________

__________

Net decrease in cash and cash equivalents

(4,081)

(123)

(630)

Cash and cash equivalents at the beginning of the period

5,289

5,895

5,895

Exchange gains/(losses) on cash and cash equivalents

169

(5)

24

__________

__________

__________

Cash and cash equivalents at the end of the period

1,377

5,767

5,289

__________

__________

__________

Notes to the Consolidated Accounts

For the period ended 30 September 2016

 

1 Preparation of the interim financial statements

These interim financial statements have been prepared under IFRS as adopted by the European Union and on the basis of the accounting policies set out in the Group's Annual Report for the year ended 31 March 2016.

 

The Group is not required to apply IAS 34 Interim Financial Reporting at this time.

These interim financial statements have not been audited and do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2016 have been delivered to the Registrar of Companies. The Auditors' Report on those accounts was unqualified and did not contain any statement under Section 498 (2) or (3) of the Companies Act 2006.

 

The Interim Report will be mailed to shareholders within the next few weeks and copies will be available on the website (www.intercede.com) and at the registered office: Intercede Group plc, Lutterworth Hall, St Mary's Road, Lutterworth, Leicestershire, LE17 4PS.

 

 

2 Revenue

All of the Group's revenue, operating (losses)/profits and net assets originate from operations in the UK. The Directors consider that the activities of the Group constitute a single business segment.

 

The split of revenue by geographical destination of the end customer can be analysed as follows:

 

 

6 months ended

30 September 2016

6 months ended 30 September 2015

Year ended 31 March 2016

£'000

£'000

£'000

UK

139

313

462

Rest of Europe

461

570

1,312

North America

1,987

4,410

8,699

Rest of World

241

254

531

__________

__________

__________

2,828

5,547

11,004

__________

__________

__________

 

 

3 Taxation

Taxation represents the net effect of amounts receivable from HMRC in respect of R&D claims and US corporation tax payable.

 

 

 

 

 

 

 

 

 

4 (Loss)/earnings per share

The calculations of the (loss)/earnings per ordinary share are based on the (loss)/profit for the period and the weighted average number of ordinary shares in issue during each period. The basic and diluted loss per share are the same as potential dilution cannot be applied to a loss making period.

 

 

6 months ended

30 September 2016

6 months ended

30 September 2015

Year ended 31 March 2016

£'000

£'000

£'000

(Loss)/profit for the period

(2,773)

480

(993)

__________

__________

__________

Number

Number

Number

Weighted average number of shares

- basic

48,507,555

48,426,005

48,429,489

- diluted

48,507,555

50,751,688

48,429,489

__________

__________

__________

Pence

Pence

Pence

Earnings/(loss) per share

- basic

(5.7)p

1.0p

(2.1)p

- diluted

(5.7)p

0.9p

(2.1)p

__________

__________

__________

 

The weighted average number of shares used in the calculation of basic and diluted earnings per share for each period were calculated as follows:

6 months ended

30 September 2016

6 months ended

30 September 2015

Year ended 31 March 2016

Number

Number

Number

Issued ordinary shares at start of period

48,735,005

48,735,005

48,735,005

Issue of ordinary shares

66,550

-

-

Effect of purchase of treasury shares

(294,000)

(309,000)

(305,516)

__________

__________

__________

Weighted average number of shares

- basic

48,507,555

48,426,005

48,429,489

__________

__________

__________

 

Add back effect of purchase of treasury shares

N/A

309,000

N/A

Effect of share options in issue

N/A

2,016,683

N/A

__________

__________

__________

Weighted average number of shares

- diluted

48,507,555

50,751,688

48,429,489

__________

__________

__________

 

5 Dividend

The Directors do not recommend the payment of a dividend.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LDLLLQLFEFBB
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.